Conatus Pharmaceuticals Profit Margin

Conatus Pharmaceuticals (CNAT) currently reports a profit margin of -68.87% as of March 2020. That compares with -57.46% in the prior-year period — down 19.9% year over year. That is below the Healthcare sector average of 14.34%. Use the charts on this page to explore Conatus Pharmaceuticals's profit margin history and peer comparisons.

Conatus Pharmaceuticals's profit margin decreased from -57.46% to -68.87% — a 19.9% year-over-year decrease (period ending March 2020). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Conatus Pharmaceuticals's profit margin of -68.87% is lower than the Healthcare sector average of 14.34%. That is roughly 580.1% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Conatus Pharmaceuticals's current -68.87% should be judged against Healthcare norms (sector average: 14.34%) and against CNAT's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of -68.87%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 14.34%. From there, open related valuation or income-statement pages for Conatus Pharmaceuticals, and consider following CNAT for alerts when major investors trade the stock.